Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30


p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.

Alexandrova EM, Mirza SA, Xu S, Schulz-Heddergott R, Marchenko ND, Moll UM.

Cell Death Dis. 2017 Mar 9;8(3):e2661. doi: 10.1038/cddis.2017.80.


ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.

Li D, Marchenko ND.

Oncotarget. 2017 Jan 24;8(4):5823-5833. doi: 10.18632/oncotarget.12878.


Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival.

Alexandrova EM, Marchenko ND.

Front Endocrinol (Lausanne). 2015 Apr 22;6:53. doi: 10.3389/fendo.2015.00053. eCollection 2015. Review.


Mitochondrial death functions of p53.

Marchenko ND, Moll UM.

Mol Cell Oncol. 2014 Oct 31;1(2):e955995. doi: 10.1080/23723548.2014.955995. eCollection 2014 Apr-Jun. Review.


p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis.

Yallowitz AR, Alexandrova EM, Talos F, Xu S, Marchenko ND, Moll UM.

Cell Death Differ. 2014 Apr;21(4):645-54. doi: 10.1038/cdd.2013.199. Epub 2014 Jan 17.


HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM.

Cell Death Dis. 2014 Jan 2;5:e980. doi: 10.1038/cddis.2013.508.


p53 opens the mitochondrial permeability transition pore to trigger necrosis.

Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM.

Cell. 2012 Jun 22;149(7):1536-48. doi: 10.1016/j.cell.2012.05.014.


Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM.

J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23. Erratum in: J Exp Med. 2012 Mar 12;209(3):640.


SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Li D, Marchenko ND, Moll UM.

Cell Death Differ. 2011 Dec;18(12):1904-13. doi: 10.1038/cdd.2011.71. Epub 2011 Jun 3.


Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.

Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM.

Cell Death Dis. 2011 May 12;2:e156. doi: 10.1038/cddis.2011.39.


Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.

Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM.

Mol Cancer Res. 2011 May;9(5):577-88. doi: 10.1158/1541-7786.MCR-10-0534. Epub 2011 Apr 8.


Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-alpha3 binding.

Marchenko ND, Hanel W, Li D, Becker K, Reich N, Moll UM.

Cell Death Differ. 2010 Feb;17(2):255-67. doi: 10.1038/cdd.2009.173. Epub 2009 Nov 20.


The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.

Vaseva AV, Marchenko ND, Moll UM.

Cell Cycle. 2009 Jun 1;8(11):1711-9. Epub 2009 Jun 30.


A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model.

Becker K, Marchenko ND, Palacios G, Moll UM.

Cell Cycle. 2008 May 1;7(9):1205-13. Epub 2008 Feb 11.


The role of ubiquitination in the direct mitochondrial death program of p53.

Marchenko ND, Moll UM.

Cell Cycle. 2007 Jul 15;6(14):1718-23. Epub 2007 May 25. Review.


Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma.

Becker K, Marchenko ND, Maurice M, Moll UM.

Cell Death Differ. 2007 Jul;14(7):1350-60. Epub 2007 Mar 23.


Monoubiquitylation promotes mitochondrial p53 translocation.

Marchenko ND, Wolff S, Erster S, Becker K, Moll UM.

EMBO J. 2007 Feb 21;26(4):923-34. Epub 2007 Feb 1.


Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells.

Marchenko ND, Marchenko GN, Weinreb RN, Lindsey JD, Kyshtoobayeva A, Crawford HC, Strongin AY.

Int J Biochem Cell Biol. 2004 May;36(5):942-56.


Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells.

Rozanov DV, Deryugina EI, Monosov EZ, Marchenko ND, Strongin AY.

Exp Cell Res. 2004 Feb 1;293(1):81-95.


The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein.

Marchenko GN, Marchenko ND, Strongin AY.

Biochem J. 2003 Jun 1;372(Pt 2):503-15.


A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction.

Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND, Quigley JP.

Cancer Res. 2002 Dec 1;62(23):7083-92.


Unconventional activation mechanisms of MMP-26, a human matrix metalloproteinase with a unique PHCGXXD cysteine-switch motif.

Marchenko ND, Marchenko GN, Strongin AY.

J Biol Chem. 2002 May 24;277(21):18967-72. Epub 2002 Mar 11.


Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells.

Sansome C, Zaika A, Marchenko ND, Moll UM.

FEBS Lett. 2001 Jan 19;488(3):110-5. Erratum in: FEBS Lett 2001 Jul 13;501(1):97-8.


Organization of threonine biosynthesis genes from the obligate methylotroph Methylobacillus flagellatus.

Marchenko GN, Marchenko ND, Tsygankov YD, Chistoserdov AY.

Microbiology. 1999 Nov;145 ( Pt 11):3273-82.


Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.

Zaika AI, Kovalev S, Marchenko ND, Moll UM.

Cancer Res. 1999 Jul 1;59(13):3257-63.


Loss of p53 function in uterine papillary serous carcinoma.

Kovalev S, Marchenko ND, Gugliotta BG, Chalas E, Chumas J, Moll UM.

Hum Pathol. 1998 Jun;29(6):613-9.


Supplemental Content

Loading ...
Support Center